Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product
- PMID: 32979224
- DOI: 10.1002/cpt.2034
Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product
References
-
- Konomi, K., Tobita, M., Kimura, K. & Sato, D. New Japanese initiative on stem cell therapies. Cell Stem Cell 16, 350-352 (2015).
-
- <https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000186471.html> (in Japanese). Accessed June 2, 2020.
-
- Sipp, D. & Okano, H. Japan strengthens regenerative medicine oversight. Cell Stem Cell 22, 153-156 (2018).
-
- Fujiwara, Y. Evolution of frameworks for expediting access to new drugs in Japan. Nat. Rev. Drug Discov. 15, 293-294 (2016).
-
- Cyranoski, D. Stem cells 2 go. Nature 573, 482-485 (2019).
MeSH terms
LinkOut - more resources
Full Text Sources
